首页|c-Met in pancreatic cancer stem cells: Therapeutic implications

c-Met in pancreatic cancer stem cells: Therapeutic implications

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
  • 维普
Pancreatic cancer is the deadliest solid cancer and currently the fourth most frequent cause of cancer-related deaths.Emerging evidence suggests that cancer stem cells (CSCs) play a crucial role in the development and progression of this disease.The identification of CSC markers could lead to the development of new therapeutic targets.In this study,the authors explore the functional role of c-Met in pancreatic CSCs,by analyzing self-renewal with sphere assays and tumorigenicity capacity in NOD SCID mice.They concluded that c-Met is a novel marker for identifying pancreatic CSCs and c-Methigh in a higher tumorigenic cancer cell population.Inhibition of c-Met with XL184 blocks self-renewal capacity in pancreatic CSCs.In pancreatic tumors established in NOD SCID mice,c-Met inhibition slowed tumor growth and reduced the population of CSCs,along with preventing the development of metastases.

Cancer stem cellsc-MetGemcitabineSelf-renewalTumorigenicity

Marta Herreros-Villanueva、Aizpea Zubia-Olascoaga、Luis Bujanda

展开 >

Division of Oncology Research,Department of Medicine, Schulze Center for Novel Therapeutics,Mayo Clinic, Rochester, MN 55905, United States

IkerChem, Oncology Therapeutics Department, 20009 San Sebastian, Spain

Department of Gastroenterology, Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas(CIBERehd), Donostia Hospital-Biodonostia Institute,University of the Basque Country, 20014 San Sebastian, Spain

2012

10.3748/wjg.v18.i38.5321

世界胃肠病学杂志(英文版)
太原消化病研治中心

世界胃肠病学杂志(英文版)

SCI
影响因子：1.001
ISSN：1007-9327
年,卷(期)：2012.18(38)
  • 2
  • 19